Tracking resistance among bacterial respiratory tract pathogens: Summary of findings of the TRUST surveillance initiative, 2001-2005

Postgraduate Medicine

Volumn 120, Issue 3, 2008, Pages 8-15

  Sahm, Daniel F ^a   Brown, Nina P ^a   Draghi, Deborah C ^a   Evangelista, Alan T ^b   Yee, Y Cheung ^b   Thornsberry, Clyde ^a  

^a Eurofins Medinet Inc   (Germany)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Haemophilus influenzae; Levofloxacin; Moraxella catarrhalis; Penicillin; Resistance; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HOSPITAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PATHOGENESIS; PENICILLIN RESISTANCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 66849125719     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.09.suppl52.279     Document Type: Article

References (34)

1. Martinez FJ. The impact of antimicrobial resistance patterns for common respiratory pathogens. Consultant. 2002;S1-S6.
2. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999 2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45(6):1721-1729.
3. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-An update. Clin Infect Dis. 2004;39(suppl 3): S142-S150. (Pubitemid 39180458)
4. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother. 2004;54(suppl 1):i23-i29. (Pubitemid 39172536)
5. Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents. 2005;25(4):282-289.
6. Jenkins SG, Farrell DJ, Patel M, et al. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect. 2005;51(5):355-363.
7. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52(2):229-246.
8. Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother. 1999;43(2):385-389.
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
10. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37(11):1405-1433.
11. Sahm DF. Resistance issues and community-acquired respiratory infections. Clin Cornerstone. 2003;(suppl 3):S4-S11. (Pubitemid 38195636)
12. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 6th ed. Wayne, PA: NCCLS; 2003.
13. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (M7-A7). Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
14. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, Streptococcus pneumoniae, 2004. Atlanta, GA: Centers for Disease Control and Prevention; 2004.
15. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42(8):2032-2035.
16. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis. 2003;45(1):63-67. (Pubitemid 36165031)
17. Broskey J, Coleman K, Gwynn MN, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother, 2000;45(suppl 1):95-99.
18. Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50(1):310-317.
19. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40(10):2321-2326.
20. Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother. 2006;57(3):442-1442 (Pubitemid 43240195)
21. Bush K, Goldschmidt R. Effectiveness of fluoroquinolones against gram-positive bacteria. Curr Opin Invest Drugs. 2000;1(1):22-30.
22. Schurck KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J Antimicrob Chemother. 2005;56(4):769-772.
23. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial Susceptibility Testing (M100-S16). Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
24. Thomson KS, Chartrand SA, Sanders CC, Block SL. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance. J Antimicrob Chemother. 1999;43(suppl C):15-19. (Pubitemid 29271922)
25. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF; TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003;36(8):963-970.
26. Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-1754. (Pubitemid 32578779)
27. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis. 2003;36(9):1132-1138. (Pubitemid 36549633)
28. Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther. 2001;23(3):425-439. (Pubitemid 32328748)
29. Kahn JB, Wiesinger BA, Xiang J. Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia: clinical and microbiological outcomes for patients treated with levofloxacin. Clin Infect Dis. 2004;38(suppl 1):S24-S33. (Pubitemid 38122238)
30. Kahn JB, Bahal N, Wiesinger BA, Xiang J. Cumulative clinical trial experience with levofloxacin for patients with community-acquired pneumonia-associated pneumococcal bacteremia. Clin Infect Dis. 2004;38(suppl 1):S34-S42. (Pubitemid 38122239)
31. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to crythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35(5):556-564.
32. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30(3):520-528. (Pubitemid 30205299)
33. Aspa J, Rajas O, Rodriguez de Castro F, et al. Pneumococcal Pneumonia in Spain Study Group. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004;38(6):787-798.
34. Johnson CN, Briles DE, Benjamin WH Jr, Hollingshead SK, Waites KB. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis. 2005;11(6):814-820.